Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04390009 · ClinicalTrials.gov registry record · Early Phase 1
Entire-body PET Scans for Multiple Sclerosis
A Early Phase 1 study of Multiple Sclerosis, sponsored by Brain Health Alliance.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04390009: Recruiting Early Phase 1 study of Multiple Sclerosis, sponsored by Brain Health Alliance.
NCT04390009 is a Early Phase 1 study of Multiple Sclerosis that is actively recruiting participants, run by Brain Health Alliance. The registered enrollment target is 20 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04390009, a Early Phase 1 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Brain Health Alliance.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.
Primary Outcome
Exploratory analysis of relative regional increases and/or decreases of Amyvid activity
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Entire-body PET-CT scans
- DRUG Amyvid radiopharmaceutical
Study Locations (1)
California
- Brain Health Alliance - Ladera Ranch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2025-12-30 |
| Phase | Early Phase 1 |
What NCT04390009 shows while recruiting
NCT04390009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Entire-body PET-CT scans is the first listed.
NCT04390009 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04390009 about?
NCT04390009 is a clinical study titled "Entire-body PET Scans for Multiple Sclerosis". To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.
What is the current status of trial NCT04390009?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2024-09-30. Estimated completion is 2025-12-30.
What conditions does trial NCT04390009 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT04390009?
The interventions under investigation include: Entire-body PET-CT scans (DIAGNOSTIC_TEST), Amyvid radiopharmaceutical (DRUG).
Who is sponsoring clinical trial NCT04390009?
This trial is sponsored by Brain Health Alliance, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04390009 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04390009's enrollment target sits among peer trials
20 262nd of 315 higher than 41 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
Assessment of Synaptic Density in MS
RECRUITING · Early Phase 1
-
Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis
ACTIVE NOT RECRUITING · Early Phase 1
-
Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis
ACTIVE NOT RECRUITING · Early Phase 1
-
Novel Imaging Markers in SPMS
COMPLETED · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI